How to Read a Peptide Study

The four questions that catch most bad claims — species, sample size, blinding, and endpoint type.

Question 1: What species?

A large fraction of peptide content online traces to rodent or cell-culture studies. Rodent efficacy results routinely fail to translate to humans; cell-culture results are hypotheses, not evidence of effect. Every entry on this site states its evidence’s species.

Question 2: How many participants?

Small trials (n<50) are noise-prone; a striking result in a small trial is more likely to be noise than the same result in a large one. Registrational trials run in the thousands for a reason.

Question 3: Was it blinded and controlled?

For subjective endpoints — energy, mood, appearance, recovery — unblinded designs are close to meaningless. If a study has no control group, it measures expectation as much as the compound.

Question 4: Endpoint or biomarker?

A change in GH level, AMPK activation, or a wound-assay metric shows a mechanism engaged. Fat lost, fractures prevented, or pain reduced are outcomes. Most peptide claims quietly substitute the first for the second.

Where to look things up

PubMed for peer-reviewed literature, ClinicalTrials.gov for registered trials and their results, and DailyMed or EMA documents for approved-product labels. This site links all three on every relevant entry.

Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.